Xeljanz (tofacitinib) 11 mg is a medication prescribed for certain autoimmune conditions. The price of Xeljanz 11 mg can vary significantly based on factors such as dosage, quantity, insurance coverage, and pharmacy.
What is the cash price for Xeljanz 11 mg?
The out-of-pocket cost for Xeljanz 11 mg can be substantial. For example, a 30-day supply of 11 mg tablets might range from approximately $6,000 to over $7,000 without insurance. Prices can fluctuate, and it is advisable to check with local pharmacies or online prescription discount services for the most current pricing.
How can I get financial assistance for Xeljanz 11 mg?
Patients prescribed Xeljanz may be eligible for financial assistance programs. Pfizer, the manufacturer of Xeljanz, offers the Xeljanz Savings Card. This program can help eligible commercially insured patients reduce their out-of-pocket costs, potentially lowering the monthly cost to as little as $10. Details on eligibility and enrollment can be found on the official Xeljanz website.
What is the difference between Xeljanz 11 mg and other strengths?
Xeljanz is available in different strengths, including 5 mg and 10 mg tablets, as well as an extended-release 11 mg tablet formulation. The 11 mg extended-release tablet is typically prescribed for initial treatment in certain conditions like ulcerative colitis [1]. The 5 mg and 10 mg strengths are usually for maintenance therapy or for different indications. The dosage and strength prescribed depend on the specific medical condition being treated and the patient's individual needs [1].
When does the patent for Xeljanz expire?
The patents protecting Xeljanz are complex and involve multiple patents covering different aspects of the drug, including its composition of matter, methods of use, and manufacturing processes. Based on information from DrugPatentWatch.com, the earliest key patents for tofacitinib have already expired or are nearing expiration. However, other patents and exclusivities may extend market protection for certain formulations or uses. For detailed information on the patent landscape and expiration dates, DrugPatentWatch.com is a valuable resource [2].
Are there generic versions of Xeljanz available?
As of early 2024, generic versions of Xeljanz (tofacitinib) are becoming available. This follows the expiration of some of the primary patents. The introduction of generic alternatives typically leads to a decrease in the overall cost of the medication.
What are the common side effects of Xeljanz?
Common side effects associated with Xeljanz can include upper respiratory tract infections, headache, diarrhea, and an increase in certain liver enzymes [1]. More serious side effects, though less common, can include serious infections, blood clots, heart attack, stroke, and certain types of cancer [1]. Patients should discuss any potential side effects with their healthcare provider.
Sources:
[1] https://www.xeljanz.com/
[2] https://drugpatentwatch.com/